The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation

Pharmacological Research

Volumn 60, Issue 6, 2009, Pages 466-474

  Nicholson, Thomas B ^a   Chen, Taiping ^a   Richard, Stéphane ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Arginine methylation; Disease; DNA damage; Post translational modifications; PRMT1

Indexed keywords

ARGININE; N(G),N(G) DIMETHYLARGININE; PREGNANE X RECEPTOR; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 1; SINEFUNGIN; STILBAMIDINE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; CARCINOGENESIS; COLON CANCER; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; ENZYME SPECIFICITY; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN METHYLATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; DNA METHYLATION; HEART DISEASES; HUMANS; KIDNEY DISEASES; METHYLATION; NEOPLASMS; PROTEIN-ARGININE N-METHYLTRANSFERASES; REPRESSOR PROTEINS;

EID: 70350084477     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.07.006     Document Type: Review

References (136)

1. Lund A.H., and van Lohuizen M. Epigenetics and cancer. Genes Dev 18 (2004) 2315-2335
2. Schneider R., Bannister A.J., and Kouzarides T. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci 27 (2002) 396-402
3. Katz J.E., Dlakic M., and Clarke S. Automated identification of putative methyltransferases from genomic open reading frames. Mol Cell Proteomics 2 (2003) 525-540
4. Cheng X., and Roberts R.J. AdoMet-dependent methylation, DNA methyltransferases and base flipping. Nucl Acids Res 29 (2001) 3784-3795
5. Alvarez-Venegas R., and Avramova Z. SET-domain proteins of the Su(var)3-9, E(z) and trithorax families. Gene 285 (2002) 25-37
6. Romano J.D., and Michaelis S. Topological and mutational analysis of Saccharomyces cerevisiae Ste14p, founding member of the isoprenylcysteine carboxyl methyltransferase family. Mol Biol Cell 12 (2001) 1957-1971
7. Zhang X., Zhou L., and Cheng X. Crystal structure of the conserved core of protein arginine methyltransferase PRMT3. EMBO J 19 (2000) 3509-3519
8. Bedford M.T., and Clarke S.G. Protein arginine methylation in mammals: who, what, and why. Mol Cell 33 (2009) 1-13
9. Bedford M.T., and Richard S. Arginine methylation: an emerging regulator of protein function. Mol Cell 18 (2005) 263-272
10. Boisvert F.M., Cote J., Boulanger M.C., and Richard S. A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics 2 (2003) 1319-1330
11. Wu C.C., MacCoss M.J., Mardones G., Finnigan C., Mogelsvang S., Yates III J.R., et al. Organellar proteomics reveals Golgi arginine dimethylation. Mol Biol Cell 15 (2004) 2907-2919
12. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119 (2004) 941-953
13. Chang B., Chen Y., Zhao Y., and Bruick R.K. JMJD6 is a histone arginine demethylase. Science 318 (2007) 444-447
14. Webby C.J., Wolf A., Gromak N., Dreger M., Kramer H., Kessler B., et al. JMJD6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science 325 (2009) 90-93
15. Cuthbert G.L., Daujat S., Snowden A.W., Erdjument-Bromage H., Hagiwara T., Yamada M., et al. Histone deimination antagonizes arginine methylation. Cell 118 (2004) 545-553
16. Wang Y., Wysocka J., Sayegh J., Lee Y.H., Perlin J.R., Leonelli L., et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306 (2004) 279-283
17. Bedford M.T. Arginine methylation at a glance. J Cell Sci 120 (2007) 4243-4246
18. Pawlak M.R., Scherer C.A., Chen J., Roshon M.J., and Ruley H.E. Arginine N-methyltransferase 1 is required for early postimplantation mouse development, but cells deficient in the enzyme are viable. Mol Cell Biol 20 (2000) 4859-4869
19. Yu Z., Chen T., Hebert J., Li E., and Richard S. A mouse PRMT1 null allele defines an essential role for arginine methylation in genome maintenance and cell proliferation. Mol Cell Biol (2009)
20. Yoshimoto T., Boehm M., Olive M., Crook M.F., San H., Langenickel T., et al. The arginine methyltransferase PRMT2 binds RB and regulates E2F function. Exp Cell Res 312 (2006) 2040-2053
21. Swiercz R., Cheng D., Kim D., and Bedford M.T. Ribosomal protein rpS2 is hypomethylated in PRMT3-deficient mice. J Biol Chem 282 (2007) 16917-16923
22. Yadav N., Lee J., Kim J., Shen J., Hu M.C., Aldaz C.M., et al. Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice. Proc Natl Acad Sci USA 100 (2003) 6464-6468
23. Lee Y.H., and Stallcup M.R. Minireview: protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol Endocrinol 23 (2009) 425-433
24. Tang J., Frankel A., Cook R.J., Kim S., Paik W.K., Williams K.R., et al. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 275 (2000) 7723-7730
25. Scorilas A., Black M.H., Talieri M., and Diamandis E.P. Genomic organization, physical mapping, and expression analysis of the human protein arginine methyltransferase 1 gene. Biochem Biophys Res Commun 278 (2000) 349-359
26. Goulet I., Gauvin G., Boisvenue S., and Cote J. Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization. J Biol Chem 282 (2007) 33009-33021
27. Cote J., Boisvert F.M., Boulanger M.C., Bedford M.T., and Richard S. Sam68 RNA binding protein is an in vivo substrate for protein arginine N-methyltransferase 1. Mol Biol Cell 14 (2003) 274-287
28. Gary J.D., Lin W.J., Yang M.C., Herschman H.R., and Clarke S. The predominant protein-arginine methyltransferase from Saccharomyces cerevisiae. J Biol Chem 271 (1996) 12585-12594
29. Henry M.F., and Silver P.A. A novel methyltransferase (Hmt1p) modifies poly(A)+-RNA-binding proteins. Mol Cell Biol 16 (1996) 3668-3678
30. Shen E.C., Henry M.F., Weiss V.H., Valentini S.R., Silver P.A., and Lee M.S. Arginine methylation facilitates the nuclear export of hnRNP proteins. Genes Dev 12 (1998) 679-691
31. Yu M.C., Lamming D.W., Eskin J.A., Sinclair D.A., and Silver P.A. The role of protein arginine methylation in the formation of silent chromatin. Genes Dev 20 (2006) 3249-3254
32. Wooderchak W.L., Zang T., Zhou Z.S., Acuna M., Tahara S.M., and Hevel J.M. Substrate profiling of PRMT1 reveals amino acid sequences that extend beyond the "RGG" paradigm. Biochemistry 47 (2008) 9456-9466
33. Fronz K., Otto S., Kolbel K., Kuhn U., Friedrich H., Schierhorn A., et al. Promiscuous modification of the nuclear poly(A)-binding protein by multiple protein-arginine methyltransferases does not affect the aggregation behavior. J Biol Chem 283 (2008) 20408-20420
34. Herrmann F., Lee J., Bedford M.T., and Fackelmayer F.O. Dynamics of human protein arginine methyltransferase 1(PRMT1) in vivo. J Biol Chem 280 (2005) 38005-38010
35. Xie Y., Ke S., Ouyang N., He J., Xie W., Bedford M.T., et al. Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. J Biol Chem (2009)
36. Lin W.J., Gary J.D., Yang M.C., Clarke S., and Herschman H.R. The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. J Biol Chem 271 (1996) 15034-15044
37. Robin-Lespinasse Y., Sentis S., Kolytcheff C., Rostan M.C., Corbo L., and Le Romancer M. hCAF1, a new regulator of PRMT1-dependent arginine methylation. J Cell Sci 120 (2007) 638-647
38. Lim Y., Kwon Y.H., Won N.H., Min B.H., Park I.S., Paik W.K., et al. Multimerization of expressed protein-arginine methyltransferases during the growth and differentiation of rat liver. Biochim Biophys Acta 1723 (2005) 240-247
39. Weiss V.H., McBride A.E., Soriano M.A., Filman D.J., Silver P.A., and Hogle J.M. The structure and oligomerization of the yeast arginine methyltransferase, Hmt1. Nat Struct Biol 7 (2000) 1165-1171
40. Zhang X., and Cheng X. Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure 11 (2003) 509-520
41. Miyata S., Mori Y., and Tohyama M. PRMT1 and Btg2 regulates neurite outgrowth of Neuro2a cells. Neurosci Lett 445 (2008) 162-165
42. Tang J., Kao P.N., and Herschman H.R. Protein-arginine methyltransferase I, the predominant protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin enhancer-binding factor 3. J Biol Chem 275 (2000) 19866-19876
43. Lee D.Y., Ianculescu I., Purcell D., Zhang X., Cheng X., and Stallcup M.R. Surface-scanning mutational analysis of protein arginine methyltransferase 1: roles of specific amino acids in methyltransferase substrate specificity, oligomerization, and coactivator function. Mol Endocrinol 21 (2007) 1381-1393
44. Lei N.Z., Zhang X.Y., Chen H.Z., Wang Y., Zhan Y.Y., Zheng Z.H., et al. A feedback regulatory loop between methyltransferase PRMT1 and orphan receptor TR3. Nucleic Acids Res (2008)
45. Higashimoto K., Kuhn P., Desai D., Cheng X., and Xu W. Phosphorylation-mediated inactivation of coactivator-associated arginine methyltransferase 1. Proc Natl Acad Sci USA 104 (2007) 12318-12323
46. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
47. Strahl B.D., Briggs S.D., Brame C.J., Caldwell J.A., Koh S.S., Ma H., et al. Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1. Curr Biol 11 (2001) 996-1000
48. Wang H., Huang Z.Q., Xia L., Feng Q., Erdjument-Bromage H., Strahl B.D., et al. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293 (2001) 853-857
49. Huang S., Litt M., and Felsenfeld G. Methylation of histone H4 by arginine methyltransferase PRMT1 is essential in vivo for many subsequent histone modifications. Genes Dev 19 (2005) 1885-1893
50. Kleinschmidt M.A., Streubel G., Samans B., Krause M., and Bauer U.M. The protein arginine methyltransferases CARM1 and PRMT1 cooperate in gene regulation. Nucleic Acids Res (2008)
51. Pal S., Vishwanath S.N., Erdjument-Bromage H., Tempst P., and Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 24 (2004) 9630-9645
52. An W., Kim J., and Roeder R.G. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117 (2004) 735-748
53. Rezai-Zadeh N., Zhang X., Namour F., Fejer G., Wen Y.D., Yao Y.L., et al. Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Genes Dev 17 (2003) 1019-1029
54. Jansson M., Durant S.T., Cho E.-C., Sheahan S., Edelmann M., Kessler B., et al. Arginine methylation regulates the p53 response. Nat Cell Biol 10 (2008) 1431-1439
55. Chevillard-Briet M., Trouche D., and Vandel L. Control of CBP co-activating activity by arginine methylation. EMBO J 21 (2002) 5457-5466
56. Xu W., Chen H., Du K., Asahara H., Tini M., Emerson B.M., et al. A transcriptional switch mediated by cofactor methylation. Science 294 (2001) 2507-2511
57. Kwak Y.T., Guo J., Prajapati S., Park K.J., Surabhi R.M., Miller B., et al. Methylation of SPT5 regulates its interaction with RNA polymerase II and transcriptional elongation properties. Mol Cell 11 (2003) 1055-1066
58. Cheng D., Cote J., Shaaban S., and Bedford M.T. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol Cell 25 (2007) 71-83
59. Cheung N., Chan L.C., Thompson A., Cleary M.L., and So C.W. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 9 (2007) 1208-1215
60. Jobert L., Argentini M., and Tora L. PRMT1 mediated methylation of TAF15 is required for its positive gene regulatory function. Exp Cell Res (2008)
61. Yamagata K., Daitoku H., Takahashi Y., Namiki K., Hisatake K., Kako K., et al. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol Cell 32 (2008) 221-231
62. McBride A.E., and Silver P.A. State of the arg: protein methylation at arginine comes of age. Cell 106 (2001) 5-8
63. Huot M.E., Brown C.M., Lamarche-Vane N., and Richard S. An adaptor role for cytoplasmic Sam68 in modulating Src activity during cell polarization. Mol Cell Biol 29 (2009) 1933-1943
64. Bedford M.T., Frankel A., Yaffe M.B., Clarke S., Leder P., and Richard S. Arginine methylation inhibits the binding of proline-rich ligands to Src homology 3, but not WW, domains. J Biol Chem 275 (2000) 16030-16036
65. Chiou Y.Y., Lin W.J., Fu S.L., and Lin C.H. Direct mass-spectrometric identification of Arg296 and Arg299 as the methylation sites of hnRNP K protein for methyltransferase PRMT1. Protein J 26 (2007) 87-93
66. Ostareck-Lederer A., Ostareck D.H., Rucknagel K.P., Schierhorn A., Moritz B., Huttelmaier S., et al. Asymmetric arginine dimethylation of heterogeneous nuclear ribonucleoprotein K by protein-arginine methyltransferase 1 inhibits its interaction with c-Src. J Biol Chem 281 (2006) 11115-11125
67. Friesen W.J., Massenet S., Paushkin S., Wyce A., and Dreyfuss G. SMN, the product of the spinal muscular atrophy gene, binds preferentially to dimethylarginine-containing protein targets. Mol Cell 7 (2001) 1111-1117
68. Selenko P., Sprangers R., Stier G., Buhler D., Fischer U., and Sattler M. SMN Tudor domain structure and its interaction with the Sm proteins. Nat Struct Mol Biol 8 (2001) 27-31
69. Cote J., and Richard S. Tudor domains bind symmetrical dimethylated arginines. J Biol Chem 280 (2005) 28476-28483
70. Godin K.S., and Varani G. How arginine-rich domains coordinate mRNA maturation events. RNA Biol 4 (2007) 69-75
71. Rho J., Choi S., Jung C.R., and Im D.S. Arginine methylation of Sam68 and SLM proteins negatively regulates their poly(U) RNA binding activity. Arch Biochem Biophys 466 (2007) 49-57
72. Chan J.Y., Hsieh T.Y., Liu S.T., Chou W.Y., Chung M.H., and Huang S.M. Physical and functional interactions between hnRNP K and PRMT family proteins. FEBS Lett 583 (2009) 281-286
73. Stetler A., Winograd C., Sayegh J., Cheever A., Patton E., Zhang X., et al. Identification and characterization of the methyl arginines in the fragile X mental retardation protein Fmrp. Hum Mol Genet 15 (2006) 87-96
74. Boisvert F.M., Chenard C.A., and Richard S. Protein interfaces in signaling regulated by arginine methylation. Sci STKE 2005 (2005) re2
75. Iwasaki H., and Yada T. Protein arginine methylation regulates insulin signaling in L6 skeletal muscle cells. Biochem Biophys Res Commun 364 (2007) 1015-1021
76. Le Romancer M., Treilleux I., Leconte N., Robin-Lespinasse Y., Sentis S., Bouchekioua-Bouzaghou K., et al. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell 31 (2008) 212-221
77. Abramovich C., Yakobson B., Chebath J., and Revel M. A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor. EMBO J 16 (1997) 260-266
78. Rizzo G., Renga B., Antonelli E., Passeri D., Pellicciari R., and Fiorucci S. The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol 68 (2005) 551-558
79. Teyssier C., Ma H., Emter R., Kralli A., and Stallcup M.R. Activation of nuclear receptor coactivator PGC-1alpha by arginine methylation. Genes Dev 19 (2005) 1466-1473
80. Barrero M.J., and Malik S. Two functional modes of a nuclear receptor-recruited arginine methyltransferase in transcriptional activation. Mol Cell 24 (2006) 233-243
81. Weber S., Maass F., Schuemann M., Krause E., Suske G., and Bauer U.M. PRMT1-mediated arginine methylation of PIAS1 regulates STAT1 signaling. Genes Dev 23 (2009) 118-132
82. Mowen K.A., Schurter B.T., Fathman J.W., David M., and Glimcher L.H. Arginine methylation of NIP45 modulates cytokine gene expression in effector T lymphocytes. Mol Cell 15 (2004) 559-571
83. Boisvert F.M., Dery U., Masson J.Y., and Richard S. Arginine methylation of MRE11 by PRMT1 is required for DNA damage checkpoint control. Genes Dev 19 (2005) 671-676
84. Barnes D.E., and Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 38 (2004) 445-476
85. Kanaar R., Wyman C., and Rothstein R. Quality control of DNA break metabolism: in the 'end', it's a good thing. EMBO J 27 (2008) 581-588
86. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 31 (2006) 402-410
87. Rogakou E.P., Boon C., Redon C., and Bonner W.M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 146 (1999) 905-916
88. Lou Z., Minter-Dykhouse K., Franco S., Gostissa M., Rivera M.A., Celeste A., et al. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell 21 (2006) 187-200
89. Huen M.S., Grant R., Manke I., Minn K., Yu X., Yaffe M.B., et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 131 (2007) 901-914
90. Kolas N.K., Chapman J.R., Nakada S., Ylanko J., Chahwan R., Sweeney F.D., et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 318 (2007) 1637-1640
91. Lee J.H., and Paull T.T. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26 (2007) 7741-7748
92. Petrini J.H., and Stracker T.H. The cellular response to DNA double-strand breaks: defining the sensors and mediators. Trends Cell Biol 13 (2003) 458-462
93. Kim H., and Chen J. New players in the BRCA1-mediated DNA damage responsive pathway. Mol Cells 25 (2008) 457-461
94. Wang B., Matsuoka S., Carpenter P.B., and Elledge S.J. 53BP1, a mediator of the DNA damage checkpoint. Science 298 (2002) 1435-1438
95. Harper J.W., and Elledge S.J. The DNA damage response: ten years after. Mol Cell 28 (2007) 739-745
96. Lobrich M., and Jeggo P.A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 7 (2007) 861-869
97. Palm W., and de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet 42 (2008) 301-334
98. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444 (2006) 633-637
99. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444 (2006) 638-642
100. Mallette F.A., and Ferbeyre G. The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 6 (2007) 1831-1836
101. Adams M.M., Wang B., Xia Z., Morales J.C., Lu X., Donehower L.A., et al. 53BP1 oligomerization is independent of its methylation by PRMT1. Cell Cycle 4 (2005) 1854-1861
102. Boisvert F.M., Hendzel M.J., Masson J.Y., and Richard S. Methylation of MRE11 regulates its nuclear compartmentalization. Cell Cycle 4 (2005) 981-989
103. Dery U., Coulombe Y., Rodrigue A., Stasiak A., Richard S., and Masson J.Y. A glycine-arginine domain in control of the human MRE11 DNA repair protein. Mol Cell Biol 28 (2008) 3058-3069
104. Boisvert F.M., Rhie A., Richard S., and Doherty A.J. The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary for 53BP1 DNA binding activity. Cell Cycle 4 (2005) 1834-1841
105. El-Andaloussi N., Valovka T., Toueille M., Hassa P.O., Gehrig P., Covic M., et al. Methylation of DNA polymerase beta by protein arginine methyltransferase 1 regulates its binding to proliferating cell nuclear antigen. FASEB J 21 (2007) 26-34
106. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 (2005) 1262-1266
107. Mathioudaki K., Papadokostopoulou A., Scorilas A., Xynopoulos D., Agnanti N., and Talieri M. The PRMT1 gene expression pattern in colon cancer. Br J Cancer 99 (2008) 2094-2099
108. Perreault A., Lemieux C., and Bachand F. Regulation of the nuclear poly(A)-binding protein by arginine methylation in fission yeast. J Biol Chem 282 (2007) 7552-7562
109. Davies J.E., Berger Z., and Rubinsztein D.C. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder. Int J Biochem Cell Biol 38 (2006) 1457-1462
110. Kwiatkowski Jr. T.J., Bosco D.A., LeClerc A.L., Tamrazian E., Vanderburg C.R., Russ C., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323 (2009) 1205-1208
111. Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323 (2009) 1208-1211
112. Smith W.A., Schurter B.T., Wong-Staal F., and David M. Arginine methylation of RNA helicase A determines its subcellular localization. J Biol Chem 279 (2004) 22795-22798
113. Rappsilber J., Friesen W.J., Paushkin S., Dreyfuss G., and Mann M. Detection of arginine dimethylated peptides by parallel precursor ion scanning mass spectrometry in positive ion mode. Anal Chem 75 (2003) 3107-3114
114. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20 Suppl. 12 (1992) S60-S62
115. Boger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38 (2006) 126-136
116. Cooke J.P. ADMA: its role in vascular disease. Vasc Med 10 Suppl. 1 (2005) S11-S17
117. Siroen M.P., Teerlink T., Nijveldt R.J., Prins H.A., Richir M.C., and van Leeuwen P.A. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 26 (2006) 203-228
118. Chan N.N., and Chan J.C. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia 45 (2002) 1609-1616
119. Sydow K., Mondon C.E., and Cooke J.P. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med 10 Suppl. 1 (2005) S35-S43
120. Jacobi J., and Tsao P.S. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol 28 (2008) 224-237
121. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
122. Wilcken D.E., Sim A.S., Wang J., and Wang X.L. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism. Mol Genet Metab 91 (2007) 309-317 [discussion 308]
123. Zakrzewicz D., and Eickelberg O. From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases. BMC Pulm Med 9 (2009) 5
124. Chen X., Niroomand F., Liu Z., Zankl A., Katus H.A., Jahn L., et al. Expression of nitric oxide related enzymes in coronary heart disease. Basic Res Cardiol 101 (2006) 346-353
125. Mookerjee R.P., Malaki M., Davies N.A., Hodges S.J., Dalton R.N., Turner C., et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 45 (2007) 62-71
126. Vedel M., Lawrence F., Robert-Gero M., and Lederer E. The antifungal antibiotic sinefungin as a very active inhibitor of methyltransferases and of the transformation of chick embryo fibroblasts by Rous sarcoma virus. Biochem Biophys Res Commun 85 (1978) 371-376
127. Wolos J.A., Frondorf K.A., and Esser R.E. Immunosuppression mediated by an inhibitor of S-adenosyl-l-homocysteine hydrolase. Prevention and treatment of collagen-induced arthritis. J Immunol 151 (1993) 526-534
128. Kolbel K., Ihling C., Bellmann-Sickert K., Neundorf I., Beck-Sickinger A.G., Sinz A., et al. Type I protein arginine methyl transferases PRMT1 and 3 act distributively. J Biol Chem (2009)
129. Obianyo O., Osborne T.C., and Thompson P.R. Kinetic mechanism of protein arginine methyltransferase 1. Biochemistry 47 (2008) 10420-10427
130. Cheng D., Yadav N., King R.W., Swanson M.S., Weinstein E.J., and Bedford M.T. Small molecule regulators of protein arginine methyltransferases. J Biol Chem 279 (2004) 23892-23899
131. Spannhoff A., Heinke R., Bauer I., Trojer P., Metzger E., Gust R., et al. Target-based approach to inhibitors of histone arginine methyltransferases. J Med Chem 50 (2007) 2319-2325
132. Heinke R., Spannhoff A., Meier R., Trojer P., Bauer I., Jung M., et al. Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors. ChemMedChem 4 (2009) 69-77
133. Ragno R., Simeoni S., Castellano S., Vicidomini C., Mai A., Caroli A., et al. Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. J Med Chem 50 (2007) 1241-1253
134. Spannhoff A., Machmur R., Heinke R., Trojer P., Bauer I., Brosch G., et al. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett 17 (2007) 4150-4153
135. Osborne T., Roska R.L., Rajski S.R., and Thompson P.R. In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. J Am Chem Soc 130 (2008) 4574-4575
136. Osborne T.C., Obianyo O., Zhang X., Cheng X., and Thompson P.R. Protein arginine methyltransferase 1: positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis. Biochemistry 46 (2007) 13370-13381